Triazolopyridazines
View Patent ↗The present invention is directed to novel compounds of formula (I) wherein the variables are defined as herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.
1. A compound of formula (I)
pharmaceutically acceptable salts thereof or isomers thereof wherein
A is heteroaryl or heterocyclyl;
R 1 is —C(O)—(C 1 -C 6 ) optionally substituted alkyl, —C(O)—O—(C 1 -C 6 ) optionally substituted alkyl, —NR a R b , —(C 1 -C 6 )alkyl —NR a —S(O) 2 —(C 1 -C 6 )alkyl or —(C 1 -C 6 )alkyl —NR a —C(O)—(C 1 -C 6 )alkyl; or
R 1 is optionally substituted (C 1 -C 6 )alkyl, optionally substituted (C 2 -C 6 )alkenyl, optionally substituted (C 3 -C 6 )cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl;
R 2 for each occurrence is independently H, OH, oxo, —(CR a R b ) x —NR a —C(O)—NR a —(C 3 -C 6 )cycloalkyl-phenyl or —(CR a R b ) x —NR a R b ; or
R 2 for each occurrence is independently optionally substituted (C 1 -C 6 )alkyl, —(CH 2 ) x — optionally substituted aryl, —(CH 2 ) x —(C 3 -C 6 ) optionally substituted cycloalkyl, —(CH 2 ) x — optionally substituted heteroaryl, or —(CH 2 ) x — optionally substituted heterocyclyl;
wherein R 2 can replace hydrogen on either nitrogen or carbon;
R 3 is aryl optionally substituted with one or more substituents;
R 4 for each occurrence is independently H, OH, halo or optionally substituted (C 1 -C 4 )alkyl;
R a and R b are independently H or optionally substituted (C 1 -C 6 )alkyl;
m is 1 or 2;
n is 0, 1 or 2; and
x for each occurrence is independently 0, 1 or 2;
provided that the compound is not
wherein R 1 is methyl, ethyl, propyl, isopropyl, t-butyl, cyclopropyl, cyclohexyl, C 2 F 5 , CF 3 , or 4-fluorophenyl;
provided that the compound is not
wherein R 1 is CF 3 , CH 3 , NH 2 or phenyl optionally substituted with Br or F;
R 2 is H or CH 3 ; and
R 3 is phenyl optionally substituted with F;
provided the compound is not
wherein R 1 is phenyl substituted with F;
R 2 is CN or NH 2 ; and
R 3 is phenyl optionally substituted with three F;
provided that the compound is not
wherein R 1 is CF 3 , CH 3 or phenyl optionally substituted with F; and
R 3 is phenyl optionally substituted with CH 3 , F or two OCH 3 ;
provided that the compound is not
wherein R 3 is phenyl substituted with three OCH 3 or phenyl substituted with two OCH 3 and one OH;
provided that the compound is not
wherein R 1 is CH 3 , CF 3 , —CH 2 CH 2 OH or phenyl optionally substituted with B, Cl or F; and
R 3 is phenyl optionally substituted with OCH 3 , CF 3 , F, isopropyl, Cl or one or two CH 3 ; or R 1 is phenyl substituted with four F and one CF 3 ; and
provided the compound is not
2. The compound according to claim 1 wherein A is
wherein R 2 can replace hydrogen on either nitrogen or carbon.
3. The compound according to claim 2 wherein R 1 is N(CH 3 ) 2 , optionally substituted (C 1 -C 6 )alkyl, optionally substituted (C 2 -C 6 )alkenyl, optionally substituted (C 3 -C 6 )cycloalkyl, optionally substituted phenyl, optionally substituted piperidinyl, optionally substituted pyrrolidinyl or tetrahydropyranyl.
4. The compound according to claim 3 wherein R 3 is phenyl optionally substituted with one or more substituents.
5. The compound according to claim 4 wherein R 2 for each occurrence is independently H and —(CH 2 ) x —NR a R b or R 2 is independently optionally substituted (C 1 -C 6 )alkyl, —(CH 2 ) x — optionally substituted phenyl, —(CH 2 ) x — optionally substituted imidazolyl, —(CH 2 ) x — optionally substituted morpholinyl, —(CH 2 ) x — optionally substituted piperidinyl, —(CH 2 ) x — optionally substituted piperazinyl or —(CH 2 ) x — optionally substituted tetrahydropyranyl.
6. The compound according to claim 5 wherein R 1 is N(CH 3 ) 2 , optionally substituted (C 3 -C 4 )alkyl, optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted phenyl or optionally substituted pyrrolidinyl.
7. The compound according to claim 6 wherein A is
wherein R 2 can replace hydrogen on either nitrogen or carbon.
8. The compound according to claim 7 wherein R 2 is H, NH 2 , optionally substituted (C 1 -C 4 )alkyl, optionally substituted phenyl or optionally substituted piperidinyl.
9. The compound according to claim 8 wherein R 3 is substituted phenyl and the substituents are independently halogen or optionally substituted (C 1 -C 4 )alkyl.
10. The compound according to claim 9 wherein R 4 is H.
11. The compound according to claim 10 wherein the compound is
12. The compound according to claim 10 wherein the compound is
13. The compound according to claim 10 wherein R 1 is isopropyl.
14. The compound according to claim 13 wherein R 2 is H.
15. The compound according to claim 14 wherein A is
wherein R 2 can replace hydrogen on either nitrogen or carbon.
16. The compound according to claim 15 wherein the compound is
17. A method of treating a condition in a patient comprising administering a therapeutically effective amount of a compound of claim 1 or a physiologically acceptable salt thereof to said patient, wherein said condition is selected from rheumatoid arthritis.
18. A pharmaceutical composition comprising
a pharmaceutically acceptable salt thereof and a pharmaceutically-acceptable carrier or excipient.